This selective inhibitor for JAK1 and JAK2 is also known to inhibit the differentiation of CD4+ naïve T cells into Th1 or Th17 cells, which possibly contributes to the pathogenesis of SLE (24). Here, JAK2 is linked to systemic lupus erythematosus.